Skip to main content
. 2022 May 31;2022:6113660. doi: 10.1155/2022/6113660

Figure 1.

Figure 1

(a) Longitudinal imaging of [18F]BCPP-EF uptake in the inguinal fat depot treated with CL-316,243 (closed red circles) demonstrated significantly higher uptake than the control (open red circles) on days 3 and 7 post treatment (∗p < 0.05 and ∗∗∗p < 0.001). [18F]FDG uptake in the inguinal fat depot treated with CL-316,243 (closed blue circles) demonstrated significantly higher uptake than the control (open blue circles) on day 7 only post treatment (∗∗∗p < 0.001; n = 10 treated and n = 5 control; data are shown as %ID/g ± SD). (b) Longitudinal imaging of [18F]BCPP-EF uptake in interscapular BAT treated with CL-316,243 (closed red circles) or control (open red circles) shows no significant difference at any time point studied. Longitudinal imaging of [18F]FDG uptake shows significantly higher uptake in interscapular BAT treated with CL-316,243 (closed blue circles) than the control (open blue circles) at day 7 post treatment (∗∗∗p < 0.001; n = 10 treated and n = 5 control; data are shown as %ID/g ± SD). (c) Blockade with L-748,382 significantly reduced [18F]BCPP-EF uptake in inguinal WAT after subchronic treatment with CL-316,243 (∗∗∗p < 0.001). (d) Blockade with L-748,382 had no significant effect [18F]BCPP-EF uptake in interscapular BAT after subchronic treatment with CL-316,243 (n = 4, data are shown as %ID/g ± SD).